September 15, 2026 · Phase 3 readout
AVIR Phase 3 readout: a negative outcome, -6.4%
On September 15, 2026, Bemnifosbuvir-Ruzasvir (BEM/RZR) — Atea Pharmaceuticals, Inc. (HEPATITIS C VIRUS CHRONIC INFECTION) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -6.4% in the window around the event. It had already run +5.3% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$4.82
1d before
$4.51
Event day
$4.62
1d after
$4.70
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.0% expected); the stock actually moved -6.4%. Model confidence at the time: 42%.
See the full scored track recordPre-catalyst setup
+5.3%
30-day run-up
3791%
30-day volatility
0.9×
volume spike